Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05218668Phase 2Active Not Recruiting

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

Role: lead

NCT04793659Phase 2Completed

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Role: lead

NCT04734379Phase 2Unknown

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Role: lead

All 3 trials loaded